Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma.

Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman S, Kwak LW, Rosen ST, Newman EM.

Clin Cancer Res. 2019 Dec 6. pii: clincanres.1768.2019. doi: 10.1158/1078-0432.CCR-19-1768. [Epub ahead of print]

PMID:
31811017
2.

Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.

Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C.

Best Pract Res Clin Haematol. 2019 Sep;32(3):239-252. doi: 10.1016/j.beha.2019.06.004. Epub 2019 Jun 6. Review.

PMID:
31585624
3.

Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.

Di Raimondo C, Abdulla FR, Zain J, Querfeld C, Rosen ST.

Br J Haematol. 2019 Nov;187(3):e79-e82. doi: 10.1111/bjh.16211. Epub 2019 Sep 30. No abstract available.

PMID:
31566707
4.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11. doi: 10.1159/000500666. [Epub ahead of print]

PMID:
31315113
5.

Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.

Buettner R, Morales C, Wu X, Sanchez JF, Li H, Melstrom LG, Rosen ST.

Mol Ther Oncolytics. 2019 May 17;14:149-158. doi: 10.1016/j.omto.2019.04.006. eCollection 2019 Sep 27.

6.

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig MA, Pichiorri F, Rosen ST.

Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227. No abstract available.

7.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.

J Cell Physiol. 2019 Feb 15. doi: 10.1002/jcp.28294. [Epub ahead of print]

PMID:
30770553
8.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29. Erratum in: Cancer. 2019 Nov 1;125(21):3893.

PMID:
30694529
9.

CD30-Positive Lymphoproliferative Disorders.

Nikolaenko L, Zain J, Rosen ST, Querfeld C.

Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.

PMID:
30596222
10.

Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.

Querfeld C, Zain J, Rosen ST.

Cancer Treat Res. 2019;176:225-248. doi: 10.1007/978-3-319-99716-2_11.

PMID:
30596221
11.

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN.

Blood. 2019 Jan 24;133(4):306-318. doi: 10.1182/blood-2018-05-851667. Epub 2018 Dec 10.

PMID:
30530749
12.

ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response.

Chang L, Shen L, Zhou H, Gao J, Pan H, Zheng L, Armstrong B, Peng Y, Peng G, Zhou BP, Rosen ST, Shen B.

Nucleic Acids Res. 2019 Jan 25;47(2):824-842. doi: 10.1093/nar/gky1199.

13.

Chimeric Antigen Receptor T-Cell Therapy.

Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST.

J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073.

PMID:
30181421
15.
16.

Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.

Folkes AS, Feng M, Zain JM, Abdulla F, Rosen ST, Querfeld C.

Curr Opin Oncol. 2018 Sep;30(5):332-337. doi: 10.1097/CCO.0000000000000468. Review.

17.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.

J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.

18.

Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.

Querfeld C, Leung S, Myskowski PL, Curran SA, Goldman DA, Heller G, Wu X, Kil SH, Sharma S, Finn KJ, Horwitz S, Moskowitz A, Mehrara B, Rosen ST, Halpern AC, Young JW.

Cancer Immunol Res. 2018 Aug;6(8):900-909. doi: 10.1158/2326-6066.CIR-17-0270. Epub 2018 Jun 12.

19.

Regulation of miR-34b/c-targeted gene expression program by SUMOylation.

Li YJ, Du L, Aldana-Masangkay G, Wang X, Urak R, Forman SJ, Rosen ST, Chen Y.

Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.

20.

Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.

Zhang XH, Nam S, Wu J, Chen CH, Liu X, Li H, McKeithan T, Gong Q, Chan WC, Yin HH, Yuan YC, Pillai R, Querfeld C, Horne D, Chen Y, Rosen ST.

J Invest Dermatol. 2018 Nov;138(11):2377-2387. doi: 10.1016/j.jid.2018.04.030. Epub 2018 Jul 14.

21.

Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.

Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, Zhou XA, Kaplan JB, Pro B, Choi J, Querfeld C, Rosen ST, Guitart J.

J Am Acad Dermatol. 2018 Jun;78(6):1068-1076. doi: 10.1016/j.jaad.2017.12.068. Epub 2018 Jan 4.

22.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.

Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.

23.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

24.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. doi: 10.1016/j.bbmt.2017.07.006. Epub 2017 Jul 18.

25.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
26.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

27.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

28.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

29.

Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.

Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C.

Br J Haematol. 2017 Jan;176(1):16-36. doi: 10.1111/bjh.14402. Epub 2016 Oct 26. Review.

PMID:
27782301
30.

An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma.

Rubio-González B, Zain J, Rosen ST, Querfeld C.

Oncology (Williston Park). 2016 Oct 15;30(10):908-13. No abstract available.

31.

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.

Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN.

Oncotarget. 2016 Nov 8;7(45):73558-73572. doi: 10.18632/oncotarget.12434.

32.

Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin.

Rubio-Gonzalez B, Zain J, Garcia L, Rosen ST, Querfeld C.

JAMA Dermatol. 2016 Dec 1;152(12):1388-1390. doi: 10.1001/jamadermatol.2016.3117. No abstract available.

PMID:
27653662
33.

Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.

Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ Jr.

J Natl Compr Canc Netw. 2016 Jul;14(7):837-47.

PMID:
27407124
34.

Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience.

Virmani P, Jawed S, Myskowski PL, Horwitz S, Skripnik Lucas A, Moskowitz A, Pulitzer M, Zain J, Rosen ST, Querfeld C.

Int J Dermatol. 2016 Nov;55(11):1248-1254. doi: 10.1111/ijd.13340.

35.

Clinical Management Updates in Mantle Cell Lymphoma.

Chen R, Sanchez J, Rosen ST.

Oncology (Williston Park). 2016 Apr;30(4):353-60. Review.

36.

Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.

Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J.

JAMA Oncol. 2016 Jun 1;2(6):790-3. doi: 10.1001/jamaoncol.2016.0004.

PMID:
27054291
37.

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.

Thomas AL, Coarfa C, Qian J, Wilkerson JJ, Rajapakshe K, Krett NL, Gunaratne PH, Rosen ST.

Nucl Recept Signal. 2015 Dec 22;13:e006. doi: 10.1621/nrs.13006. eCollection 2015.

38.

Tumor microenvironment in mycosis fungoides and Sézary syndrome.

Rubio Gonzalez B, Zain J, Rosen ST, Querfeld C.

Curr Opin Oncol. 2016 Jan;28(1):88-96. doi: 10.1097/CCO.0000000000000243. Review.

PMID:
26632770
39.

Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome.

Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C.

Dermatol Clin. 2015 Oct;33(4):807-18. doi: 10.1016/j.det.2015.05.014. Epub 2015 Jul 29. Review.

40.

Elevated incidence of fractures in women with invasive breast cancer.

Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA.

Osteoporos Int. 2016 Feb;27(2):499-507. doi: 10.1007/s00198-015-3246-3. Epub 2015 Aug 21.

PMID:
26294292
42.

In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM, Nooka AK, Rosen ST, Hruz PW, Schiltz GE, Shanmugam M.

J Biol Chem. 2015 Jun 5;290(23):14441-53. doi: 10.1074/jbc.M114.628826. Epub 2015 Apr 6.

43.

Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.

Siddiqi T, Rosen ST.

Oncology (Williston Park). 2015 Mar;29(3):198-203. Review.

44.

Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.

Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen ST, Shanmugam M.

Clin Cancer Res. 2015 Mar 1;21(5):1161-71. doi: 10.1158/1078-0432.CCR-14-1088. Epub 2014 Dec 26.

45.

Chronic lymphocytic leukemia: a clinical review.

Nabhan C, Rosen ST.

JAMA. 2014 Dec 3;312(21):2265-76. doi: 10.1001/jama.2014.14553. Review.

PMID:
25461996
46.

An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.

Bhave M, Shah AN, Akhter N, Rosen ST.

Curr Opin Oncol. 2014 Nov;26(6):590-9. doi: 10.1097/CCO.0000000000000132. Review.

PMID:
25233068
47.

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A.

J Clin Oncol. 2015 Mar 1;33(7):732-9. doi: 10.1200/JCO.2013.52.3522. Epub 2014 Sep 15.

PMID:
25225420
48.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM.

Ann Oncol. 2014 Nov;25(11):2211-7. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5.

49.

Identification of p38β as a therapeutic target for the treatment of Sézary syndrome.

Bliss-Moreau M, Coarfa C, Gunaratne PH, Guitart J, Krett NL, Rosen ST.

J Invest Dermatol. 2015 Feb;135(2):599-608. doi: 10.1038/jid.2014.367. Epub 2014 Aug 22.

50.

Cardiovascular toxicity of biologic agents for cancer therapy.

Bhave M, Akhter N, Rosen ST.

Oncology (Williston Park). 2014 Jun;28(6):482-90. Review.

Supplemental Content

Loading ...
Support Center